ZLDPF — Zealand Pharma A/S/ADR
—
OTC ·
Unknown ·
Unknown ·
CIK 2068427 ·
Denmark
Last close
$40.00
Market Cap
$2.71B
52W High
$83.12
52W Low
$35.93
ADV30
775
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 4,491,000,000 | 4,491,000,000 | 3,859,000,000 | 3,917,000,000 | 19,762,000,000 | 4,038,000,000 | 1,762,000,000 |
| Mar 2026 | 34,000,000 | 34,000,000 | -539,000,000 | -394,000,000 | 15,301,000,000 | 3,849,000,000 | 832,000,000 |
| Dec 2025 | 68,915,000 | 68,915,000 | -356,544,000 | -379,115,000 | 15,948,798,000 | 4,576,541,000 | 1,118,185,000 |
| Sep 2025 | 49,569,000 | 49,569,000 | -461,320,000 | -404,233,000 | 16,797,246,000 | 5,972,711,000 | 1,634,645,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$6,360,933,000
Investing CF
$-2,919,506,000
Financing CF
$-385,182,000
CapEx
$-72,073,000
Dividends Paid
—
Buybacks
$-74,762,000
EPS Diluted TTM
$89.54
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-356,000,000
Inventory
$0
Receivables
—
ST Investments
$10,619,000,000
EBIT TTM
$6,970,190,000
Pretax Income TTM
$6,943,782,000
Interest Exp TTM
$26,408,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,643,859,968
EBITDA
$2,324,047,104
Free Cash Flow
$-2,063,679,360
Enterprise Value
$-10,827,876,352
Total Cash
$14,456,999,936
Total Debt
$411,000,000
Shares Out
67,693,163
Trailing EPS
$6.09
Book Value
$40.56
ROE
16.3%
ROA
7.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 9,214,860,000 | 7,113,523,000 | 6,455,008,000 | 15,948,798,000 | 1,118,185,000 | 14,830,613,000 | 6,531,933,000 |
| Dec 2024 | 62,691,000 | -1,269,071,000 | -1,078,828,000 | 9,505,600,000 | 888,858,000 | 8,616,742,000 | -930,816,000 |
| Dec 2023 | 342,788,000 | -577,217,000 | -703,739,000 | 1,979,993,000 | 387,154,000 | 1,592,839,000 | -425,668,000 |
| Dec 2022 | 103,986,000 | -816,599,000 | -1,202,135,000 | 1,539,806,000 | 723,895,000 | 815,911,000 | -942,311,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.16
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RDW | Redwire Corp | $2.72B | $10.88 | — |
| PTXKY | PT XLSMART Telecom Sejahtera Tbk/ADR | $2.68B | $2.94 | — |
| MGEE | MGE ENERGY INC | $2.67B | $70.77 | — |
| BATRK | Atlanta Braves Holdings, Inc. | $2.75B | $52.03 | — |
| QS | QuantumScape Corp | $2.64B | $4.57 | — |
News headlines (Yahoo Finance, 1h cache)
Zealand Pharma announces opening of new Research Hub in Cambridge, Massachusetts
2026-10-01 13:30 · Yahoo
Zealand Pharma Reports 13.1% Weight Loss in Phase 3 Survodutide Trial
2026-10-01 09:29 · Yahoo
Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and t
2026-10-01 07:30 · Yahoo
Total number of shares and voting rights in Zealand Pharma as of September 30, 2026
2026-09-30 20:00 · Yahoo
Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology
2026-09-29 22:03 · Yahoo
Zealand Pharma - Transactions related to share buy-back program (week 39, 2026)
2026-09-28 15:00 · Yahoo
Zealand Pharma announces initiation of the registrational Phase 3 ZUPREME program of petrelintide in people with overweight or obesity
2026-09-22 15:00 · Yahoo
Zealand Pharma - Transactions related to share buy-back program (week 38, 2026)
2026-09-21 15:00 · Yahoo
Zealand Pharma receives positive CHMP opinion for Zeydovio™ (glepaglutide) for the treatment of short bowel syndrome
2026-09-18 10:10 · Yahoo
Zealand Pharma (CPSE:ZEAL) Grants Exclusive Type 1 Diabetes Peptide License
2026-09-18 09:14 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.